Stock SLN SILENCE THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Silence Therapeutics plc

Equities

SLN

US82686Q1013

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
20.6 USD -2.69% Intraday chart for Silence Therapeutics plc +13.12% +18.60%
Jul. 12 European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading MT
Jul. 08 European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading MT

Evolution of the average Target Price on Silence Therapeutics plc

Price target over the last 5 years

History of analyst recommendation changes

08b5f7a640a01f1098482e80b65.mlpDFiuuTPErScAcFOQhcwvmgwx3t_nfADkjki8AQtY.0ikqfhreLaFtZJdPda1zQ12-5GQD04-6cGNQ42BncITCIy5OQNsNsHh4qw~1950c207acde90d5938914130d4de4c3

Analyst Recommendations on Silence Therapeutics plc

Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating MT
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating MT
Chardan Boosts Price Target on Silence Therapeutics to $42 From $26 on Positive Data From Zerlasiran Study, Keeps Buy Rating MT
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating MT
BMO Capital Starts Silence Therapeutics With Outperform Rating, $67 Price Target MT
HC Wainwright Adjusts Silence Therapeutics Price Target to $75 From $80, Maintains Buy Rating MT
Chardan Adjusts Price Target on Silence Therapeutics to $26 From $29, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
20.6 USD
Average target price
59.2 USD
Spread / Average Target
+187.38%
High Price Target
75 USD
Spread / Highest target
+264.08%
Low Price Target
49 USD
Spread / Lowest Target
+137.86%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Silence Therapeutics plc

Chardan Research
Morgan Stanley
BMO Capital
HC Wainwright

Ratings for Silence Therapeutics plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SLN Stock
  4. Consensus Silence Therapeutics plc